CAR T-cell therapy is the best option for patients with relapsed/refractory follicular lymphoma, even though it comes with serious side effects.
For patients with relapsed/refractory follicular lymphoma , chimeric antigen responder T-cell therapy offers the best chance of survival, despite its high rate of serious side effects and the need to travel to infusion centers. Alternatively, updated chemo+immunotherapy regimens and bispecific antibodies provide less rigorous but effective treatment options for low-risk patients who cannot tolerate or access CAR T .
The most significant drawback of treatment with axicabtagene ciloleucel is cytokine release syndrome and neurotoxicity, which occurred at grade 3 and higher in 6% and 15% of ZUMA-5 participants, respectively.At a median follow up of 29 months, CR among patients in the ELARA study was 68.1%, and the overall response rate was 86.2%. Fewer than half of patients had any CRS, and none had grade three or higher.
"About 20% of patients will experience an early recurrence or progression of diseases within 24 months which is associated with worse outcomes. About half of those patients experienced transformation, so they have diffuse large B-cell lymphoma, and they're getting CAR T-cells.
In addition to the possibly durable nature of bispecific antibodies, they induce cytokine release syndrome at a much lower rate than CAR T, and most side effects are manageable in an outpatient setting,"usually just with Tylenol occasionally with a dose of steroids," said Dr Martin. Dr Jacobson observed that"Dr Martin is looking at the 80% of people who do really well with follicular lymphoma. Those are the people who don't require a third line of therapy. They are the people who don't have PoD-24. I'm looking at the 20% of people who either do require a third line of therapy or who do have PoD-24, and we're not treating nearly enough of those patients with follicular lymphoma.
Non-Hodgkin Lymphoma NHL Biologic Therapy Biologics Chimeric Antigen Receptor T-Cell Therapy Chimeric Antigen Receptors Chimeric Immunoreceptors Chimeric T-Cell Receptors Artificial T-Cell Receptors CAR T Chimaeric Antigen Receptor T-Cell Therapy Chimaeric Antigen Receptors Chimaeric Immunoreceptors Chimaeric T-Cell Receptors Follicular Lymphoma Lymphoma
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Car Companies Can Generate $1600 Per Car In Future From Connected Car ServicesSarwant has over 29 years of work experience in leading major advisory and transformation engagements focusing on making organizations future ready. Sarwant is currently working with Markets and Markets as President and Chief Commercial office.
Read more »
Dallas Eclipse Forecast: Low clouds could spoil the fun, but timing is everythingWill clouds ruin the view of the total solar eclipse in North Texas? It could all come down to timing.
Read more »
2024 solar eclipse guide: Timing, path, glasses and everything to knowThe 2024 solar eclipse will bring an incredible spectacle to skies next week, marking a rare and historic moment not just in the U.S., but in Illinois. For…
Read more »
GloRilla Talks JT Feud on 2024 CMT Music Awards Red Carpet: ‘Everything Is Everything’GloRilla says 'everything is everything' when asked about her back-and-forth spat with City Girls rapper JT on X over the weekend.
Read more »
31 Storage Products For Decluttering*Deep breaths* — a place for everything and everything in its place.
Read more »
2024 Beijing motor show previewEverything you need to know about the new metal at China's largest car show
Read more »